Legis Daily

Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

USA116th CongressS-476| Senate 
| Updated: 2/13/2019
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (5)
Edward J. Markey (Democratic)Christopher A. Coons (Democratic)Thomas R. Carper (Democratic)Jon Tester (Democratic)Sherrod Brown (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 This bill establishes a series of requirements relating to drug rebates and discounts under Medicare and Medicare Advantage (MA). Specifically, for each pharmacy benefits manager (PBM) that contracts with a prescription drug plan (PDP) under Medicare or MA, or with a qualified health benefits plan offered through a health insurance exchange, HHS must publish on its website (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies. As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan. The bill also modifies requirements regarding Medicare enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 13, 2019
Introduced in Senate
Feb 13, 2019
Read twice and referred to the Committee on Finance.
  • February 13, 2019
    Introduced in Senate


  • February 13, 2019
    Read twice and referred to the Committee on Finance.

Health

Government information and archivesHealth care costs and insuranceInflation and pricesMedicarePrescription drugs

Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

USA116th CongressS-476| Senate 
| Updated: 2/13/2019
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 This bill establishes a series of requirements relating to drug rebates and discounts under Medicare and Medicare Advantage (MA). Specifically, for each pharmacy benefits manager (PBM) that contracts with a prescription drug plan (PDP) under Medicare or MA, or with a qualified health benefits plan offered through a health insurance exchange, HHS must publish on its website (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies. As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan. The bill also modifies requirements regarding Medicare enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 13, 2019
Introduced in Senate
Feb 13, 2019
Read twice and referred to the Committee on Finance.
  • February 13, 2019
    Introduced in Senate


  • February 13, 2019
    Read twice and referred to the Committee on Finance.
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (5)
Edward J. Markey (Democratic)Christopher A. Coons (Democratic)Thomas R. Carper (Democratic)Jon Tester (Democratic)Sherrod Brown (Democratic)

Finance Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Government information and archivesHealth care costs and insuranceInflation and pricesMedicarePrescription drugs